Control of the immune response by pro-angiogenic factors
about
Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the FateTargeting the tumor vasculature to enhance T cell activityImmunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.Sunitinib-induced morpho-functional changes and drug effectiveness in malignant solitary fibrous tumoursAnti-CD27 Antibody Potentiates Antitumor Effect of Dendritic Cell-Based Vaccine in Prostate Cancer-Bearing Mice.Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication.Human Mesenchymal Stromal Cells Transplantation May Enhance or Inhibit 4T1 Murine Breast Adenocarcinoma through Different ApproachesCell type- and tumor zone-specific expression of pVEGFR-1 and its ligands influence colon cancer metastasis.Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer.Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients.Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid CancerThe recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases.Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancerPD-1(+) and Foxp3(+) T cell reduction correlates with survival of HCC patients after sorafenib therapyAtezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis.Angiogenic factors and inflammation in steroid-refractory acute graft-vs-host disease.PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidenceMelanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretionStructural Determinant and Its Underlying Molecular Mechanism of STPC2 Related to Anti-Angiogenic ActivityImmune Regulation by T Regulatory Cells in Hepatitis B Virus-Related Inflammation and Cancer.MicroRNA-34a promotes genomic instability by a broad suppression of genome maintenance mechanisms downstream of the oncogene KSHV-vGPCR.Immunotherapy of colorectal cancer: new perspectives after a long path.Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.Commentary: A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment.Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinomaThe route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response.Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells.Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer.
P2860
Q26777205-D96464E1-BC39-423A-A2D0-D481FE9E6C0CQ27026329-9FC832AB-EAA8-4797-9338-7286F7574C0DQ28078539-ABBDA327-D50F-4FDB-A2B4-2616A325D0FCQ30275254-19ABBCD5-2AC4-4DDE-B1E9-29EC2BC2B7C1Q33433105-C757BC9E-CE14-4704-A234-BD937E1AAB31Q34993204-634C8402-ACB6-435B-B9FC-515FDBCB20A0Q35506659-19DF1E73-9AFC-45C3-B06B-EE726F2F9AC4Q35592434-D43D81EA-2645-4260-8C7F-4D346E2E4FD3Q35603983-9BCC7173-12F1-4CF4-A7EA-EDE6A48594ACQ35627827-A13A4DE2-1D60-46E1-B497-BB2E1C3961F7Q36420167-1FCCCBAD-7915-4D38-87E4-162E2E254178Q36553576-CF192222-6C0C-49DB-B6B7-907673241002Q36730827-B5247204-1A56-4909-BC6C-0F7EE752B664Q36854062-14D67F7C-5C0D-41F0-8395-49CD4091D1E5Q37024656-D5A47A75-566C-466D-B892-570254696065Q37057942-2E22EC32-D430-416B-9FD9-BABCA79B113AQ37075642-9DF16F57-CA21-4152-A31A-60D5272C9A36Q37079133-C067A46A-0CE6-40E2-A0CE-884E48C1AE1AQ37179971-ED548732-B5C5-4077-8D6B-8C84BF9DE8BFQ37237228-803A7273-A37E-4F78-BF75-7B4B838367A1Q37678218-25996F09-CE07-4BF9-AF0F-B66A85B63D85Q38539063-F901EBEF-C519-4BC7-9F13-CA3A1FD2E588Q38649562-F3A66C98-362A-4AD6-97A9-37EFDEC06208Q38706890-EBFD986C-FF13-4D76-BA5F-8028AF8C9389Q38715245-A0D3F2CD-9CD8-44E8-9CA2-E46A11FB655BQ38767613-9DF6D78A-2EE1-4C05-822C-F13B66804BD1Q38794695-F16F7ABF-B5CA-4DD1-91FE-AA68845D6FFBQ39043413-810651B9-D880-4AFB-BC8D-AED7EF0522E1Q40535967-F05AE13A-0E4E-41B6-AA3E-19FE80465058Q40979902-BAFDEF15-F478-4B22-A974-14D02F29B9AEQ40985733-AC88D554-9AB9-4284-94D6-17144CCE590EQ41147045-FCCEF8CD-70CD-457A-A82A-F6C45654CEFFQ41588307-DBEA737A-59A2-49E0-970F-2A1C3391115FQ41813115-D65A7A60-A5A9-4E52-B453-0B48EA2BFAD6Q47104348-0EC1FEF9-F09A-422A-A029-3412BE8AB93BQ47114407-E82C7ECC-1ACD-483D-BBFD-E75204418E4AQ47350013-3FBBC317-F06F-4861-B894-CFB3B465B40EQ49382862-2CAF5E99-F42D-4147-8C83-CACA319A9FABQ50019794-8DB47F1D-5AA3-44BF-A05E-FB759387A719Q50550722-0A9B06B2-B9D0-49A1-87D7-FCC0734F9D61
P2860
Control of the immune response by pro-angiogenic factors
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Control of the immune response by pro-angiogenic factors
@ast
Control of the immune response by pro-angiogenic factors
@en
Control of the immune response by pro-angiogenic factors
@nl
type
label
Control of the immune response by pro-angiogenic factors
@ast
Control of the immune response by pro-angiogenic factors
@en
Control of the immune response by pro-angiogenic factors
@nl
prefLabel
Control of the immune response by pro-angiogenic factors
@ast
Control of the immune response by pro-angiogenic factors
@en
Control of the immune response by pro-angiogenic factors
@nl
P2093
P2860
P50
P3181
P356
P1476
Control of the immune response by pro-angiogenic factors
@en
P2093
Elie Marcheteau
Orianne Colussi
Simon Pernot
Thibault Voron
P2860
P3181
P356
10.3389/FONC.2014.00070
P407
P577
2014-01-01T00:00:00Z